Infographic: 5 Key Biosimilars Terms Defined

At the AAM Biosimilar Council Conference 2017, Hillel Cohen, executive director of scientific affairs at Sandoz, disambiguated key terms in biosimilars.
The Center for Biosimilars Staff
September 17, 2017
At the AAM Biosimilar Council Conference 2017, Hillel Cohen, executive director of scientific affairs at Sandoz, disambiguated key terms in biosimilars.


infographic with definitions for biosimilarity, interchangeability, transition, switching, and substitution in biosimilars

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.